Header Logo

Connection

JOHN KIRKWOOD to Integrin alphaVbeta3

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Integrin alphaVbeta3.
JOHN KIRKWOOD
Connection Strength
0.175
Integrin alphaVbeta3
  1. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J Immunother. 2010 Apr; 33(3):316-25.
    View in: PubMed
    Score: 0.087
  2. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
    View in: PubMed
    Score: 0.087
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.